Voyager Therapeutics (VYGR) Jumps: Stock Rises 7.8%
Voyager Therapeutics, Inc. VYGR was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 69.8% in the past one-month time frame.
The company has seen two negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Voyager Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Voyager Therapeutics, Inc. Price
Voyager Therapeutics, Inc. Price | Voyager Therapeutics, Inc. Quote
A better-ranked stock in the Medical sector is Mylan N.V. MYL, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Is HSTM going up? Or down? Predict to see what others think: Up or Down
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Mylan N.V. (MYL) : Free Stock Analysis Report
Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
